Telo Genomics Launches Physician Experience Program in the United States
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, is excited to announce the initiation of their Physician Experience Program - SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation). SMART is an observational study intended for cancer treating physicians and their staff in the US to gain experience...
2023-11-16 9:15 AM EST
Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists
Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A), (the "Company" or "Telo"), a biotech company pioneering the most comprehensive A.I. based genomic medical testing, is excited to announce that the College of American Pathologists (CAP) Accreditation Office has informed the company that its certification application has been successfully completed. The company may now proceed to an external assessment audit, the final step to...
2023-11-07 8:45 AM EST
American Society of Hematology (ASH) Accepts Validation Data from Telo Genomics for Presentation at Upcoming Annual Meeting
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") announces today that the American Society of Hematology (ASH) has accepted the results of TeloView-SMM technical repeatability validation for presentation at their annual meeting in December of this year. The study was led by Dr. Hans Knecht, MD, Director of the Division of Hematology at McGill University and the Jewish General Hospital, Montreal, Canada. The...
2023-11-01 8:45 AM EDT
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
Toronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has passed all requirements and received its Certificate of Accreditation of ISO 15189. Importantly, the rigorous ISO 15189 is the international standard specific for medical laboratories and a key ccomplishment in the commercialization of Telo Genomic's platform of novel cancer assays, which are based-on the 3D analysis of telomeres...
2023-10-26 8:45 AM EDT
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM - An Important Commercial Milestone Achieved
Toronto, Ontario--(Newsfile Corp. - October 17, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") today announced the launch of its TeloViewSMM to clinicians in the United States. Combining molecular biology and artificial intelligence, the diagnostic platform performs industry-leading 6-factor quantitative analysis of 3D telomeres, the protective end caps of chromosomes. TeloView has the potential to characterize multiple cancers, identify their current level...
2023-10-17 8:45 AM EDT
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
Toronto, Ontario--(Newsfile Corp. - October 12, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has participated in the International Myeloma Society ("IMS") annual meeting that took place in Athens, Greece during the last week of September 2023. Telo presented positive results in assessing minimal residual disease ("MRD") in multiple myeloma ("MM"). The data presented demonstrated repeatable sensitivity three-fold higher than...
2023-10-12 9:46 AM EDT
Telo Genomics Achieves Noteworthy International Standards Organization ("ISO") Regulatory Accreditation
Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is proud to announce that it has successfully completed the final assessment and achieved ISO 15189 accreditation. ISO 15189 is the international standard specific for clinical laboratories. The ISO 15189 accreditation qualifies Telo to offer its TeloView tests as laboratory developed tests (LDTs) for clinical use from its central laboratory in Toronto. In...
2023-09-06 9:00 AM EDT
Telo Genomics Reports Substantial Progress Toward Clinical Launch of TeloView-SMM
Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to provide an update on the planned launch of the TeloView®SMM (Smoldering Multiple Myeloma) assay in the fourth quarter of this year. The test will be introduced to clinicians as a Research Use Only (RUO) tool via Telo's new physician experience program. The program, designated as SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation),...
2023-08-29 4:36 PM EDT
Telo Genomics Announces Agreement for Strategic Advisory Services
Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has entered into an agreement with Leede Jones Gable Inc. ("Leede") to compensate Leede for strategic advice provided in connection with the Company's recently closed $0.25 non-brokered private placement ("Offering"). Under the agreement, the Company will issue to Leede 150,000 common shares in the capital of the Company, and grant 75,000 common...
2023-06-30 8:45 AM EDT
Telo Genomics Completes Oversubscribed Private Placement
Toronto, Ontario--(Newsfile Corp. - June 14, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") announces that it has closed its previously announced non-brokered private placement ("Offering") of units (the "Units"). The Company issued a total of 11,335,500 Units at a price of $0.25 per Unit for gross proceeds of $2,833,875. Each Unit issued consisted of one common share of the Company (a "Common Share") and one-half of one non-transferable common share...
2023-06-14 8:45 AM EDT
Telo Genomics Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023
Toronto, Ontario--(Newsfile Corp. - June 12, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") presented the results of its latest study on Friday June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting. This study, executed in conjunction with the Mayo Clinic, was conducted to confirm the utility of the TeloView technology to identify newly diagnosed multiple myeloma (NDMM) patients with a high-risk to relapse within 1 year while...
2023-06-12 8:45 AM EDT
Telo Genomics Announces Private Placement Increased to $2,766,375 from Previously Announced Private Placement of $2,000,000
Toronto, Ontario--(Newsfile Corp. - June 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has increased the size of its previously announced non-brokered private placement ("Offering") from up to $2 million in proceeds to $2,766,375 and 11,065,500 units (the "Units" or each a "Unit"). Each Unit will consist of one common share of the Company (a "Common Share") and one-half of one non-transferable common share purchase warrant...
2023-06-06 4:05 PM EDT
Telo Genomics Presents Superior Results of Its Smoldering Multiple Myeloma Studies at ASCO 2023
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce that the results of its smoldering multiple myeloma (SMM) studies that were conducted in collaboration with the Mayo Clinic were presented earlier today at the American Society of Clinical Oncology (ASCO) 2023 annual meeting. A total of 178 SMM patients were included in the study. The study results revealed a superior accuracy of 80% to stratify...
2023-06-05 9:30 AM EDT
Telo Genomics Announces Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - May 19, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.25 per Unit for gross proceeds of $2,000,000 (the "Offering"). Each Unit will consist of one common share of the Company (a "Common Share") and one-half of one non-transferable common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder...
2023-05-19 8:00 AM EDT
Telo Genomics' Multiple Myeloma Drug Resistance Study Results Have Been Selected for Presentation at the 2023 European Hematology Congress
Toronto, Ontario--(Newsfile Corp. - May 4, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that the abstract submitted to the European Hematology Association (EHA) 2023 annual congress was accepted for presentation and will be published in the official proceedings of the meeting. The abstract summarizes the results to date of the second clinical study that Telo is conducting in collaboration with the Mayo Clinic. The study's objective...
2023-05-04 8:30 AM EDT
Telo Genomics Achieves a Major Milestone - Results of Smoldering Myeloma Study Accepted for Presentation at ASCO Annual Meeting
Toronto, Ontario--(Newsfile Corp. - April 13, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) 2023 annual meeting was accepted for presentation and will be published in the official proceedings of the meeting. The results summarized in the abstract are under embargo according to ASCO rules and regulations until the abstract is published online on May 25,...
2023-04-13 4:00 AM EDT
Telo Genomics Advances to Final Stage of Achieving ISO Certification
Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has recently completed the interim assessment of its systems and protocols for ISO 15189 certification with over 90% compliance. ISO 15189 is the international standard specific for clinical laboratories. The completion of this critical step qualifies Telo to advance to the external audit stage, which is the final stage of the ISO...
2023-03-15 8:30 AM EDT
Telo Genomics Launches Multiple Myeloma Advisory Board at the American Society of Hematology Annual Meeting
Toronto, Ontario--(Newsfile Corp. - February 22, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce the launch of our inaugural multiple myeloma clinical advisory board ("MM CAB"). The advisory group met at the American Society of Hematology ("ASH") meeting in New Orleans on December 13, 2022. This internationally recognized group of clinical advisors provided feedback and advice to the Telo management team in advance of the company's...
2023-02-22 8:30 AM EST
Telo Genomics Appoints Kris Weinberg as Chief Executive Officer
Toronto, Ontario--(Newsfile Corp. - December 12, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the appointment of Kris Weinberg as Chief Executive Officer ("CEO"), effective today. Telo Genomics' current CEO, Sherif Louis PhD, will assume the position of President & Chief Technology Officer. "These executive changes are integral to TELO's long term growth strategy," said John Meekison, Telo Genomics Board Director & Chair of the Audit...
2022-12-12 8:45 AM EST
Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual Meeting
Toronto, Ontario--(Newsfile Corp. - December 8, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the formation of a multiple myeloma advisory board ("MM Advisory Board"). Driven by the success of TELO's recent clinical studies, announced on September 14, 2022, and as part of the Company's commercialization strategy, the Company has prioritized the formation of an internationally recognized clinical advisory board to help guide the...
2022-12-08 8:30 AM EST